<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049360</url>
  </required_header>
  <id_info>
    <org_study_id>LAC-MD-27</org_study_id>
    <nct_id>NCT01049360</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo</brief_title>
  <acronym>LAC-MD-27</acronym>
  <official_title>Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of this multicenter, randomized,
      double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study
      comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or
      with placebo, aclidinium bromide and formoterol fumarate, all administered twice a day (BID)
      in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD)
      beginning with a 2-week run-in period and with a 7-10 day washout each between treatment
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)</measure>
    <time_frame>0 to 12 hours post-dose on Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Aclidinium 400 μg / Formoterol 12 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium 400 μg / formoterol 6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium 400 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400 μg administered twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol 12 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate 12 μg twice-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium 400 μg / Formoterol 12 μg</intervention_name>
    <description>Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.</description>
    <arm_group_label>Aclidinium 400 μg / Formoterol 12 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium 400 μg / Formoterol 6 μg</intervention_name>
    <description>Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.</description>
    <arm_group_label>Aclidinium 400 μg / formoterol 6 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium 400 μg</intervention_name>
    <description>Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.</description>
    <arm_group_label>Aclidinium 400 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 12 μg</intervention_name>
    <description>Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.</description>
    <arm_group_label>Formoterol 12 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand the study procedures and be willing to participate in the study as
             indicated by signing the ICF and HIPAA form

          -  Be male or female aged 40 to 80 years, inclusive

          -  Have a diagnosis of stable, moderate to severe COPD (stages II and III) as defined by
             guidelines of the Global Initiative for Chronic Obstructive Lung Disease (2008)

          -  Be a current or former cigarette smoker with a smoking history of at least 10
             pack-years

          -  Have post-albuterol/salbutamol FEV1 values ≥ 30% and &lt; 80% of the predicted value.
             FEV1 will be measured at the Screening Visit (Visit 1) between 10 and 15 minutes after
             inhalation of albuterol/salbutamol.

          -  Have post-albuterol/salbutamol FEV1/FVC values &lt; 70% (ie, 100 × post-
             albuterol/salbutamol FEV1/FVC &lt; 70%).

          -  If female, be at least 1 year postmenopausal or surgically sterile (defined as having
             a hysterectomy or tubal ligation). Women of childbearing potential must have a
             negative serum β-human chorionic gonadotropin pregnancy test at screening

          -  Be in good stable health (as judged by the Investigator) other than the COPD, based on
             medical history, physical examination, ECG, spirometry, and clinical laboratory data
             evaluations

          -  Have COPD symptoms and FEV1 values at the time of randomization that are stable
             compared with those at Screening (Visit 1), according to the Investigator's medical
             judgment

        Exclusion Criteria:

          -  Have been hospitalized for an acute COPD exacerbation within 3 months before screening

          -  Have any respiratory tract infection (including the upper respiratory tract) or signs
             of a COPD exacerbation or respiratory infection in the 6 weeks before Screening (Visit
             1).

          -  Have any clinically significant respiratory conditions other than COPD

          -  Have a history or presence of asthma verified from medical records

          -  Have used theophylline (including long-acting theophylline) within the previous 3
             months before study entry

          -  Have Stage II hypertension, defined as systolic pressure of 160 and above, and
             diastolic pressure of 100 and above

          -  Chronic use of oxygen therapy ≥ 15 hours a day

          -  Have a history, current diagnosis, or presence of exercise-induced bronchospasm

          -  Have a body mass index ≥ 40 kg/m2

          -  Have participated in an pulmonary rehabilitation program within the previous 3 months

          -  Have clinically significant cardiovascular conditions

          -  Have uncontrolled infection resulting from human immunodeficiency virus and/or active
             hepatitis

          -  Have symptomatic prostatic hypertrophy and/or bladder neck obstruction.

          -  Have narrow-angle glaucoma

          -  Have a history of hypersensitivity reaction (including report of paradoxical
             bronchospasm) to inhaled anticholinergics (including aclidinium bromide), β2
             adrenergic agonists, or any other inhaled medication or any component thereof

          -  Have a QTcB, as indicated in the centralized reading report, above 470 msec in the
             resting ECGs performed at Screening (Visit 1) and/or patients who are using
             medications that may prolong the QT interval

          -  Have clinically relevant abnormalities in the results of clinical laboratory tests, in
             ECG parameters other than QTc, in results of the physical examination,

          -  Have any concurrent medical condition that, in the judgment of the Investigator, might
             interfere with the conduct of the study, confound the interpretation of the study
             results, or endanger the patient's well-being

          -  Do not maintain regular day/night, waking/sleeping cycles (eg, patients with history
             of sleep apnea syndrome or any disease related with sleep disturbances such as
             restless legs syndrome or somnambulism)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forest Investigative Site 0909</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2050</name>
      <address>
        <city>Pheonix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2029</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1084</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2045</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1152</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2053</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2047</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1431</name>
      <address>
        <city>N. Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2084</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1119</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2035</name>
      <address>
        <city>Elizabeth city</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1153</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2028</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2043</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1106</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1089</name>
      <address>
        <city>E. Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1121</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1498</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1129</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4066&amp;filename=lac-md-27-synopsis.pdf</url>
    <description>lac-md-27-synopsis</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>September 22, 2016</results_first_submitted>
  <results_first_submitted_qc>September 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2016</results_first_posted>
  <disposition_first_submitted>September 30, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2011</disposition_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Airflow Obstruction, Chronic</keyword>
  <keyword>Chronic Airflow Obstruction</keyword>
  <keyword>Chronic Obstructive Airway Disease</keyword>
  <keyword>Chronic Obstructive Lung Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in a total of 20 study centers in the United States. The first patient was screened in December 2009 and the last patient visit was in August 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Aclidiunium/Formoterol 400/6 - Aclidiunium/Formoterol 400/12 - Aclidinium - Formoterol</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Aclidinium/Formoterol 400/12 - Aclidinium - Formoterol - Placebo</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Aclidinium - Formoterol - Placebo - Aclidinium/Formoterol 400/6</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Formoterol - Placebo - Aclidinium/Formoterol 400/6 - Aclidinium/Formoterol 400/12</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5</title>
          <description>Placebo - Aclidinium/Formoterol 400/6 - Aclidinium/Formoterol 400/12 - Aclidinium</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6</title>
          <description>Aclidinium/Formoterol 400/6 - Aclidinium - Placebo - Aclidinium/Formoterol 400/12</description>
        </group>
        <group group_id="P7">
          <title>Sequence 7</title>
          <description>Aclidinium/Formoterol 400/12 - Formoterol - Aclidinium/Formoterol 400/6 - Aclidinium</description>
        </group>
        <group group_id="P8">
          <title>Sequence 8</title>
          <description>Aclidinium - Placebo - Aclidinium/Formoterol 400/12 - Formoterol</description>
        </group>
        <group group_id="P9">
          <title>Sequence 9</title>
          <description>Formoterol - Aclidinium/Formoterol 400/6 - Aclidinium - Placebo</description>
        </group>
        <group group_id="P10">
          <title>Sequence 10</title>
          <description>Placebo - Aclidinium/Formoterol 400/12 - Formoterol - Aclidinium/Formoterol 400/6</description>
        </group>
        <group group_id="P11">
          <title>Sequence 11</title>
          <description>Aclidinium/Formoterol 400/6 - Formoterol - Aclidinium/Formoterol 400/12 - Placebo</description>
        </group>
        <group group_id="P12">
          <title>Sequence 12</title>
          <description>Aclidinium/Formoterol 400/12 - Placebo - Aclidinium - Aclidinium/Formoterol 400/6</description>
        </group>
        <group group_id="P13">
          <title>Sequence 13</title>
          <description>Aclidinium - Aclidinium/Formoterol 400/6 - Formoterol - Aclidinium/Formoterol 400/12</description>
        </group>
        <group group_id="P14">
          <title>Sequence 14</title>
          <description>Formoterol - Aclidinium/Formoterol 400/12 - Placebo - Aclidinium</description>
        </group>
        <group group_id="P15">
          <title>Sequence 15</title>
          <description>Placebo - Aclidinium - Aclidinium/Formoterol 400/6 - Formoterol</description>
        </group>
        <group group_id="P16">
          <title>Sequence 16</title>
          <description>Aclidinium/Formoterol 400/6 - Placebo - Formoterol - Aclidinium</description>
        </group>
        <group group_id="P17">
          <title>Sequence 17</title>
          <description>Aclidinium/Formoterol 400/12 - Aclidinium/Formoterol 400/6 - Placebo - Formoterol</description>
        </group>
        <group group_id="P18">
          <title>Sequence 18</title>
          <description>Aclidinium - Aclidinium/Formoterol 400/12 - Aclidinium/Formoterol 400/6 - Placebo</description>
        </group>
        <group group_id="P19">
          <title>Sequence 19</title>
          <description>Formoterol - Aclidinium - Aclidinium/Formoterol 400/12 - Aclidinium/Formoterol 400/6</description>
        </group>
        <group group_id="P20">
          <title>Sequence 20</title>
          <description>Placebo - Formoterol - Aclidinium - Aclidinium/Formoterol 400/12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inc/exc criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="6"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="5"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="5"/>
                <participants group_id="P20" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Population</title>
          <description>Safety population defined as all randomized patients who took at least one dose of double-blind investigational product</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)</title>
        <time_frame>0 to 12 hours post-dose on Day 14</time_frame>
        <population>ITT Population defined as randomized patients who took at least one dose of double-blind investigational product and who had at least 1 baseline and 1 post-baseline assessment of FEV1</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 400 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 400 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Aclidinium bromide 400 μg administered twice-daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg twice-daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo twice-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)</title>
          <population>ITT Population defined as randomized patients who took at least one dose of double-blind investigational product and who had at least 1 baseline and 1 post-baseline assessment of FEV1</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.187" spread="0.019"/>
                    <measurement group_id="O2" value="0.189" spread="0.018"/>
                    <measurement group_id="O3" value="0.144" spread="0.018"/>
                    <measurement group_id="O4" value="0.114" spread="0.019"/>
                    <measurement group_id="O5" value="-0.013" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Treatment and period were fixed effects, subjects was random effect, and baseline values at each period were a covariate</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean difference</param_type>
            <param_value>0.200</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period were fixed effects, subjects was random effect, and baseline values at each period were a covariate</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>0.202</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.158</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Day 14</time_frame>
        <population>ITT Population defined as randomized patients who took at least one dose of double-blind investigational product and who had at least 1 baseline and 1 post-baseline assessment of FEV1</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 400 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 400 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Aclidinium bromide 400 μg administered twice-daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg twice-daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo twice-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as randomized patients who took at least one dose of double-blind investigational product and who had at least 1 baseline and 1 post-baseline assessment of FEV1</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.124" spread="0.018"/>
                    <measurement group_id="O2" value="0.129" spread="0.018"/>
                    <measurement group_id="O3" value="0.080" spread="0.018"/>
                    <measurement group_id="O4" value="0.071" spread="0.018"/>
                    <measurement group_id="O5" value="-0.008" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period were fixed effects, subjects was random effect, and baseline values at each period were a covariate</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period were fixed effects, subjects was random effect, and baseline values at each period were a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Day 14</time_frame>
        <population>ITT Population defined as randomized patients who took at least one dose of double-blind investigational product and who had at least 1 baseline and 1 post-baseline assessment of FEV1</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium 400 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 400 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Aclidinium bromide 400 μg administered twice-daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumarate 12 μg twice-daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo twice-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as randomized patients who took at least one dose of double-blind investigational product and who had at least 1 baseline and 1 post-baseline assessment of FEV1</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.355" spread="0.022"/>
                    <measurement group_id="O2" value="0.348" spread="0.021"/>
                    <measurement group_id="O3" value="0.260" spread="0.021"/>
                    <measurement group_id="O4" value="0.245" spread="0.022"/>
                    <measurement group_id="O5" value="0.073" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period were fixed effects, subjects was random effect, and baseline values at each period were a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.281</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.230</ci_lower_limit>
            <ci_upper_limit>0.333</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period were fixed effects, subjects was random effect, and baseline values at each period were a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.275</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.224</ci_lower_limit>
            <ci_upper_limit>0.325</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days after the last dose of investigational product, for up to 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aclidinium 400 μg / Formoterol 12 μg</title>
          <description>Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>Aclidinium 400 μg / Formoterol 6 μg</title>
          <description>Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)</description>
        </group>
        <group group_id="E3">
          <title>Aclidinium 400 μg</title>
          <description>Aclidinium bromide 400 μg administered twice-daily (BID)</description>
        </group>
        <group group_id="E4">
          <title>Formoterol 12 μg</title>
          <description>Formoterol fumarate 12 μg twice-daily</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo twice-daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the Investigator will be subject to mutual agreement between the investigator and sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Esther Garcia</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

